logo-loader
viewTissue Regenix Group PLC

Tissue Regenix’s CellRight signs multi-year distribution agreement with Arthrex Inc.

The regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics and advanced surgical instruments and techniques to help influence better patient outcomes

X-Ray of knees
CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures

Tissue Regenix Group PLC (LON:TRX) shares jumped 6% higher on Tuesday as the firm announced that its subsidiary, CellRight Technologies has signed a long-term, multi-year distribution agreement with Arthrex Inc., a premier orthopaedic surgical solutions company.

The AIM-listed regenerative medical devices company said the multi-year commitment will give surgeons access to verified osteobiologics - materials that help heal bone defects - and advanced surgical instruments and techniques to help influence better patient outcomes.

READ: Tissue Regenix launches new unit as it inks US distribution deal

CellRight provides osteobiologics for use in orthopaedic, spine and foot, and ankle procedures to enhance healing of defects caused by trauma or disease.

Steve Couldwell, Tissue Regenix's chief executive, commented: "This is a flagship distribution agreement for CellRight and the wider Tissue Regenix Group. It highlights the value of strategic partnerships with prestigious companies in this space.”

Jesus Hernandez, chief executive of CellRight, added: "This long-term distribution agreement will allow physicians and patients better access to CellRight's innovative orthobiologics through the Arthrex network".

In late morning trading, Tissue Regenix shares were 6.1% higher at 8.75p.

 -- Adds share price --

Quick facts: Tissue Regenix Group PLC

Price: 0.4499 GBX

AIM:TRX
Market: AIM
Market Cap: £5.27 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Tissue Regenix increasing throughput in its facility to meet 'exceptional...

Tissue Regenix PLC's (LON:TRX) Gareth Jones caught up with Proactive's Andrew Scott to update on developments in the regenerative medical devices maker's second half. ''The focus is really on increasing throughput in our San Antonia facility in the United States to allow us to meet the demand...

on 19/12/19

2 min read